A comparison of the US Pharmacopeia and the European Pharmacopeia

Abstract

The United States Pharmacopeia-National Formulary (USP–NF) and the European Pharmacopoeia (Ph. Eur.) are significant to compare, as both serve as essential reference guides for numerous member states and countries, in addition to other national and regional pharmacopoeias. The study employed a qualitative comparative documentary analysis, utilizing a "Compressed Vertical Analysis" approach, to compare the Hypromellose and Povidone monographs. Hypromellose and povidone were selected as model excipients to explore the complexities of pharmacopeial harmonization. Hypromellose, a widely used polymer in solid oral dosage forms, offers broad applicability and analytical richness due to its complex polymeric structure and diverse test parameters, including chemical assays and viscosity. In contrast, povidone, officially designated as a harmonized monograph (PDG code E-32), provides a case study in the practical challenges of harmonization. Despite its formal status, the monograph exhibits notable differences in identification methods and K-value determination across pharmacopoeias, underscoring persistent compendial divergences and their industrial implications. The study followed a three-stage analytical procedure: granular-level monograph comparison, mid-level general chapter contextualization, and high-level interpretive linking to regulatory and philosophical frameworks. Results indicate significant harmonization in core quality attributes. For both excipients, fundamental definitions are aligned. Hypromellose's assay and viscosity determinations are fully harmonized, as are Povidone's nitrogen content assay and several impurity limits. However, notable divergences persist. Povidone exhibits distinct identification schemes, with USP-NF retaining non-harmonized national tests, and subtle differences in K-value sample preparation. Hypromellose shows structural differences, such as the Ph. Eur.'s explicit "Characters" section and "Appearance of Solution" test, absent in USP-NF. A key philosophical divergence is the Ph. Eur.'s inclusion of non-mandatory Functionality Related Characteristics (FRC) sections, absent in USP-NF monographs, reflecting different approaches to excipient performance guidance. This study highlights the ongoing complexity in global pharmacopeial standards. It emphasizes that 'harmonized' does not imply 'interchangeable,' necessitating a nuanced industry approach that considers both compendial requirements and a scientific understanding of excipient functionality for improved public health outcomes.